Rare Cancers, Diagnostic Challenges and Personalized Therapeutic Approaches in the 21st Century
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 20 February 2025 | Viewed by 190
Special Issue Editors
Interests: computational cancer genomics; next generation sequencing; targeted therapy; immunotherapy; target discovery; drug repurposing; rare cancers
Special Issues, Collections and Topics in MDPI journals
Interests: cancer epidemiology; cancer diagnosis; genomic profiling of cancer; emerging therapies in cancer, neuroendocrine neoplasm; melanoma
Special Issues, Collections and Topics in MDPI journals
Interests: bladder cancer; kidney cancer; prostate cancer; testicular cancer; castrate-resistant prostate cancer; adjuvant therapy; immunotherapy; health services and outcomes; rare cancer
Special Issue Information
Dear Colleagues,
Rare cancers, as defined by the National Cancer Institute in the US, have an incidence of less than 15 cases per 100,000 people per annum. They comprise about 200 cancer types, and nearly one-fourth of all new cancer cases in the US are rare. Because of low case counts, studying rare cancers represents a challenge. This is reflected in a limited understanding of their biology, challenges with diagnosis and classification, non-uniform standards of care, and generally poor outcomes. Personalized therapeutic approaches, based on advances in cancer biology and novel markers, are yielding promising changes to this landscape. In this Special Issue, we invite researchers to submit original research manuscripts and reviews on diagnostic challenges, advances in cancer biology, and novel therapeutic approaches to rare cancers.
Dr. Jason Roszik
Dr. Asad Ullah
Dr. Nabin Raj Karki
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- rare cancer
- biology
- diagnosis
- classification
- personalized therapeutics
- markers
